Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

European Journal of Neurology

Volumn 17, Issue 5, 2010, Pages 672-676

  Uzawa, A ^a   Mori, M ^a   Hayakawa, S ^a   Masuda, S ^a   Kuwabara, S ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antiaquaporin 4 antibody; Interferon beta 1b; Multiple sclerosis; Neuromyelitis optica; Relapse; Treatment

Indexed keywords

INTERFERON BETA SERINE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SIDE EFFECT; SKIN ULCER; SURVIVAL RATE;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-BETA; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROMYELITIS OPTICA; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77950881518     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02897.x     Document Type: Article

References (15)

1. The IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 45 : 1277 1285.
2. Saida T, Tashiro H, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005 64 : 621 630. (Pubitemid 40261889)
3. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998 51 : 682 689. (Pubitemid 28449243)
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007 6 : 805 815.
5. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007 69 : 2221 2231.
6. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 130 : 1206 1223. (Pubitemid 47355945)
7. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007 130 : 1235 1243. (Pubitemid 47355956)
8. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 202 : 473 477.
9. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 358 : 676 688. (Pubitemid 351240747)
10. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 66 : 1485 1489.
11. Hayakawa S, Mori M, Okuta A, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008 196 : 181 187.
12. Papeix C, Vidal J-S, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007 13 : 256 259. (Pubitemid 46592781)
13. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002 125 : 1450 1461. (Pubitemid 34755161)
14. Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999 162 : 74 83. (Pubitemid 29064122)
15. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 2008 255 : 305 307.